The Cancer Money Trail: What Does Each Country Contribute?
If cancer is a global disease, the distribution of cancer research money is one of the most important parts of the story.
Part 2 showed where major cancer research funding comes from. Part 3 asks where that money is geographically concentrated. The answer matters because cancer burden is global, while research capacity and funding are not distributed evenly.
The global map begins with a defined dataset
The most useful comparison available for this investigation is the 2016–2023 analysis of public and philanthropic cancer research awards. It identified 107,955 awards worth $51.4 billion and linked those awards to approximately 431,700 publications.
Again, this is not a census of every dollar spent on cancer. It excludes or incompletely captures commercial R&D and reflects the methodology and country affiliations used by the researchers. It is nevertheless large enough to reveal a clear pattern.
The United States
U.S.-based funders provided approximately $29.3 billion, or 57.2%, of the investment captured. NIH alone represented approximately $21.9 billion, or 42.6%.
The scale of U.S. funding means that changes in American research budgets can have effects beyond American laboratories. U.S. institutions also sit at the centre of international research networks, publications, trials and technology development.
The United Kingdom
The UK accounted for approximately $5.7 billion, or 11.1%, of the identified funding. That makes the UK the second-largest national contributor in the dataset.
The UK's role is not limited to one organisation. Public funding, charitable funding and university-based research interact, with organisations such as Cancer Research UK supporting research programmes and infrastructure across the country.
Australia and Canada
Australia contributed approximately $1.5 billion, or 2.9%, while Canada contributed approximately $1.3 billion, or 2.6%. Together, they illustrate how a small group of high-income countries can account for a disproportionate share of global research investment.
These figures also show why country rankings need context. A country's absolute contribution can be large while its research investment relative to population, GDP or cancer burden tells a different story.
Japan, China and Europe
The analysis places Japan at approximately 3.6% and China at approximately 2.6% of the funding captured. The European Union and member states together represented approximately 16.8% under the study's grouping approach.
These figures should not be added mechanically to the U.S., UK, Australia and Canada figures because grouping conventions can overlap with national classifications. The underlying study should always be used when comparing the categories.
The Commonwealth
The Commonwealth collectively contributed about $8.7 billion, or 17.0%, of the identified investment. The largest contributors within that group included the UK, Australia and Canada.
The collective number is useful for understanding networks, but it can also hide major differences between wealthy Commonwealth countries and lower-income members. A country can belong to the same international association without having anything like the same research infrastructure.
The high-income concentration
The most striking figure is broader than any single country: high-income countries accounted for about $50.0 billion, or 97.0%, of the funding identified.
Low-income countries received about $8.4 million, less than 0.1%. Measured another way, the study found a large gap in investment per cancer-associated disability-adjusted life year. This does not mean low-income countries do no research. It means the international funding system recorded dramatically less investment associated with them.
Research capacity can reinforce itself
Funding and research capacity can form a feedback loop. Well-funded institutions can employ specialist scientists, maintain laboratories, run clinical trials, collect data and publish results. Those outputs can strengthen future grant applications and international collaborations.
Countries without those systems face the opposite problem. A shortage of infrastructure can make it harder to win grants, which can make it harder to build infrastructure. The geographic concentration therefore raises a question of capacity, not simply charity.
What cancers receive attention?
The global study found that breast cancer received about $5.3 billion, or 10.3%, of the funding captured when looking at specified cancer sites. Blood cancers received about $4.7 billion, or 9%. General cancer research, where no specific site was assigned, accounted for about $16.5 billion, or 32.1%.
Funding by cancer type cannot be judged solely by case numbers. Scientific opportunity, mortality, existing knowledge, disease biology, patient populations, fundraising and the cost of conducting research can all affect funding patterns.
The clinical-trial gap
The same analysis found that clinical trials received about 7.3% of the public and philanthropic funding identified, while preclinical science received about 76%. WHO separately reported in 2025 that cancer clinical trials remained concentrated in high-income countries and that 63 countries had no registered cancer trials in the data examined.
WHO also highlighted liver, cervical and stomach cancers as among the cancers causing major mortality in low- and middle-income countries but receiving comparatively less research attention, and noted that surgery, radiotherapy, diagnostics and palliative care were underrepresented relative to novel drug research.
What the map does not prove
A funding map is not a map of scientific quality. It does not prove that one country produces better science than another, nor does it prove that a heavily funded cancer has received “too much” money. It also does not establish that money spent in a wealthy country benefits only that country; research can generate knowledge, technologies and treatments used internationally.
The question that follows the money
Knowing which countries contribute is only the middle of the trail. Money is normally awarded to organisations, not abstract countries. The next stage therefore follows the money one level deeper: cancer centres, universities, investigators, projects and the institutions that control or administer the resulting research.
Both sides. One record. Evidence before conclusions. Primary sources are prioritised. Facts, estimates and uncertainty are distinguished, and figures are not combined when their definitions, periods or coverage are materially different.